Safety of nimotuzumab following clinical trials in head and neck epithelial tumors
Context: Immunotherapy, by directing the immune response against tumor cells, complements the oncological therapy along with conventional treatments. Thus, the monoclonal antibody nimotuzumab blocks the binding of epidermal growth factor to its receptor, interfering with cell proliferation in epithe...
שמור ב:
| Principais autores: | , , , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
GarVal Editorial Ltda.
2021-05-01
|
| סדרה: | Journal of Pharmacy & Pharmacognosy Research |
| נושאים: | |
| גישה מקוונת: | https://jppres.com/jppres/pdf/vol9/jppres20.958_9.3.324.pdf |
| תגים: |
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|